Harrow Health

HROW

Harrow Health, formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company (NASDAQ: HROW) based in Nashville, TN. The change of name to Harrow Health in January 2019 reflected a goal of "creating, investing in, operating and growing a diversified portfolio of health care businesses that meet the needs of health care providers and patients across America", according to CEO Mark Baum.Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, one of the nation's leading ophthalmic-focused pharmaceutical companies. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company (NASDAQ: ETON). In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 Series A financing.In July 2019, Harrow Health announced the launch of Mayfield Pharmaceuticals, a subsidiary focused on developing branded pharmaceutical products for women. In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its Chief Innovation Officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.

Harrow Health has been a target of short sellers for a while. The current short interest of 19.94% is slightly above the average of the last 12 months (17.23%).